Xanadu, a fun-loving Labrador retriever, was diagnosed with osteosarcoma of his right front leg in August 2010. Lisa Dowell chronicled her dog’s ensuing struggle in...
Displaying 1 - 10 of 110 results
Researchers will investigate the effectiveness of combining radiation therapy with an immune-stimulating agent to help slow the spread of osteosarcoma, the most common bone tumor in dogs.
September 19, 2016 – Osteosarcoma is the most common primary bone tumor of dogs, with 10,000 new diagnoses each year. 1 It is most commonly...
June 25, 2019 – Sometimes it starts with a misstep, or subtle lameness. Sometimes it starts with a small lump on the leg that becomes...
Researchers are investigating the effectiveness of a novel immunotherapy to help reduce metastatic disease (cancer spread) and prolong quality of life in dogs with osteosarcoma.
Researchers will investigate the role of a signaling pathway in the progression of bone cancer in dogs and evaluate its potential as a new therapeutic target to help treat this disease.
Researchers will explore metabolic drivers of cancer growth and look for new therapy targets for osteosarcoma, the most common type of bone cancer in dogs.
This study will characterize the expression of toll-like receptors, which activate the immune system, in canine osteosarcoma cells to better determine the biological consequences associated with activating these receptors.
Researchers are studying a group of 80 dogs with osteosarcoma to generate comparison data for ongoing and future studies of new chemotherapeutic agents.
Researchers are evaluating the effectiveness of oral rapamycin as an adjunct, postsurgery therapy to combat cancer spread (metastasis) in client-owned dogs.